On October 16, 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending that the European Union grant a marketing authorisation for Foundayo — the brand name for orforglipron, Eli Lilly's once-daily oral GLP-1 medicine — in two indications at once: weight management and type 2 diabetes. If the European Commission follows the recommendation, the EU joins the United States, where the FDA approved the pill on April 1, 2026.
The structural detail is the story: orforglipron is not a peptide. It is a small, non-peptide molecule that activates the GLP-1 receptor — EMA's own description — which is what makes possible a once-daily tablet taken any time of day, with or without food and water. Behind the opinion sit two weight-management studies (4,740 adults, 72 weeks, roughly 5% to 11% body-weight loss versus 2% to 2.5% on placebo) and four type 2 diabetes studies (3,765 adults, HbA1c down 1.2 to 1.9 percentage points). This piece covers what the committee recommended, where those numbers come from, and what still stands between this opinion and a European launch.
What the CHMP recommended
The positive opinion, announced by EMA on October 16, 2026, recommends granting an EU-wide marketing authorisation for Foundayo (orforglipron). The applicant is Eli Lilly Nederland B.V., and the recommendation covers two indications. In weight management, Foundayo is intended for adults with obesity (a body-mass index of 30 or above), or overweight (BMI 27 to under 30) with at least one weight-related health problem, used alongside diet and increased physical activity. In type 2 diabetes, it is intended for adults whose blood glucose is not sufficiently controlled by diet and exercise — on its own where metformin is unsuitable, or together with other diabetes medicines.
EMA's announcement is careful about what a CHMP opinion is: an intermediary step on the path to approval, not the approval itself. The medicine would remain prescription-only wherever it is eventually authorised. Nothing about today's opinion puts the pill in a European pharmacy — the Commission's decision comes first, then each country's pricing and reimbursement processes.
A GLP-1 pill that isn't a peptide
Orforglipron is a small, non-peptide molecule that activates the GLP-1 receptor — that is EMA's description, and it is the single fact that explains why this approval lane exists. Every injectable in the class is a peptide. The one oral GLP-1 already on the market, semaglutide (Rybelsus), is also a peptide, formulated as a tablet whose absorption depends on taking it under specific conditions. Foundayo carries no such restrictions: EMA describes a once-daily tablet taken any time of day, with or without food, and Lilly built its entire launch framing around that property when the FDA approved the medicine in the United States on April 1, 2026 — the only GLP-1 pill for weight loss without food or water restrictions, in the company's words.
The molecule was discovered by Chugai Pharmaceutical and licensed to Lilly in 2018, according to Lilly's approval release. EMA's summary describes a treatment that starts at a low dose and is increased over time, with nausea, vomiting and diarrhoea as the most common side effects — most frequent during the dose-escalation period. Those are properties of the medicine as reviewed, not a description of what anyone should do; it is prescription-only in every scenario the regulator describes.
The numbers behind the opinion
For weight, EMA's summary pools two studies totalling 4,740 adults followed for 72 weeks: participants lost roughly 5% to 11% of body weight depending on dose, against roughly 2% to 2.5% on placebo. Lilly identifies its obesity registration program as ATTAIN — ATTAIN-1 and ATTAIN-2 — and its April release reported the highest studied dose in ATTAIN-1 (3,127 adults randomised) delivering 12.4% average weight loss versus 0.9% on placebo at 72 weeks on the efficacy estimand, or 11.1% versus 2.1% regardless of treatment completion. The EMA range spans pooled doses and studies; Lilly's figures isolate the top dose of one trial.
For type 2 diabetes, EMA pooled four studies covering 3,765 adults: HbA1c fell by 1.2 to 1.9 percentage points depending on dose, versus 0.4 to 0.8 points on placebo. The same summary benchmarks the medicine against active comparators — 0.8 points for dapagliflozin 10 mg, and 1.2 to 1.5 points for oral semaglutide at 7 mg and 14 mg. Lilly's type 2 diabetes studies of orforglipron run under the ACHIEVE name — the series whose head-to-head arm against oral semaglutide we covered in the ACHIEVE-3 results.
Every figure above is a population average produced under trial conditions. None of it is a forecast for any individual, and the side-effect and discontinuation data from the same programs are part of the evidence, not a footnote to it.
What happens next: the European Commission decides
The CHMP opinion now passes to the European Commission, which issues the binding decision granting — or refusing — an EU-wide marketing authorisation. EMA's announcement sets no timeline for that decision. It also spells out what follows even a favourable one: pricing and reimbursement are decided at Member State level, which is where actual availability in any given country is determined. An EU authorisation is the door; national health systems decide how quickly it opens.
Lilly said at its US approval that it has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each shortly after approval. Whether Europe's rollout tracks that ambition depends on the reimbursement conversations that follow the Commission's decision. The regulatory timeline will carry the decision when it lands.
The oral-GLP-1 landscape if the EU says yes
If authorised, Foundayo enters a market where oral semaglutide is the incumbent pill — a peptide tablet with administration restrictions Foundayo does not carry, and the comparator EMA's own summary benchmarks on HbA1c — 1.2 to 1.9 points across orforglipron's four pooled diabetes studies, against benchmarks of 1.2 to 1.5 points for oral semaglutide at 7 mg and 14 mg. Those ranges come from different studies and doses; they are not a matched comparison, and the actual head-to-head picture is more nuanced than a single pooled figure — exactly what our orforglipron vs semaglutide comparison walks through dose by dose; orforglipron vs tirzepatide sets the pill against the strongest injectables in the class.
Lilly is also studying orforglipron beyond weight and glucose: its release lists ongoing research programs in obstructive sleep apnoea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence. None of that is in the CHMP recommendation — those are pipeline indications, not labels.
What this does and doesn't change today
Today's opinion changes nothing by itself. Foundayo has not received EU marketing authorisation; a Commission decision is pending, and national pricing, reimbursement and launch arrangements would follow separately — that is what stands between this announcement and any European prescription. What has already changed is informational: the evidence package that convinced both the FDA and now Europe's regulator is public, specific and comparable — which makes it harder for unlicensed sellers to blur what the trials did and did not show.
One boundary is worth stating plainly. Orforglipron is an approved small-molecule prescription medicine, not an unapproved research peptide: products sold outside the licensed supply chain are unlicensed copies of an approved drug, not gray-zone research chemicals. Our orforglipron profile and the regulatory timeline track what happens next.